These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32901994)

  • 1. Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment.
    Yousefi N; Polroudi Moghaddam M; Afsharmanesh G; Peiravian F
    Int J Health Plann Manage; 2020 Nov; 35(6):1503-1511. PubMed ID: 32901994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.
    Main B; Csanadi M; Ozieranski P
    Health Econ Policy Law; 2022 Jul; 17(3):348-365. PubMed ID: 35382921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea.
    Kim W; Koo H; Lee HJ; Han E
    Int J Health Policy Manag; 2022 Oct; 11(10):2198-2207. PubMed ID: 34814666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.
    Nguyen TA; Knight R; Roughead EE; Brooks G; Mant A
    Health Policy Plan; 2015 Mar; 30(2):267-80. PubMed ID: 24425694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
    Rigter H
    Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Policy in Hungary.
    Inotai A; Csanádi M; Harsányi A; Németh B
    Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spending on pharmaceuticals in Italy: macro constraints with local autonomy.
    Mapelli V; Lucioni C
    Value Health; 2003; 6 Suppl 1():S31-45. PubMed ID: 12846924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.
    Cho MH; Yoo KB; Lee HY; Lee KS; Kwon JA; Han KT; Kim JH; Park EC
    Health Policy; 2015 May; 119(5):604-11. PubMed ID: 25630635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
    Hsu JC; Lu CY
    Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview.
    Verghese NR; Barrenetxea J; Bhargava Y; Agrawal S; Finkelstein EA
    J Mark Access Health Policy; 2019; 7(1):1601060. PubMed ID: 31007877
    [No Abstract]   [Full Text] [Related]  

  • 17. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
    Maniadakis N; Kourlaba G; Shen J; Holtorf A
    BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.